Markets:

News

Articles published by Inflammasome Therapeutics

Inflammasome Therapeutics Completes Enrollment of Multicenter Phase II Dose- Ranging Study for First-in-Class Dual Inflammasome Inhibitor, K8, to Treat Geographic Atrophy

November 25, 2025

From Inflammasome Therapeutics

Via Business Wire

Inflammasome Therapeutics to Collaborate with Sean M. Healey & AMG Center for ALS on a new treatment for Amyotrophic Lateral Sclerosis (ALS)

November 13, 2025

From Inflammasome Therapeutics

Via Business Wire

Inflammasome Therapeutics’ K8 Implant Cuts Lesion Growth by more than 50% in Geographic Atrophy after Three Months in Multi-Center Trial

September 11, 2025

From Inflammasome Therapeutics

Via Business Wire

Inflammasome Therapeutics Announces Topline 3-month Data from a Clinical Trial of its First-in-Class Dual Inflammasome Inhibitor, K8, in Geographic Atrophy, Demonstrating Rapid, Substantial and Significant Efficacy and Safety

January 15, 2025

From Inflammasome Therapeutics

Via Business Wire

Inflammasome Therapeutics Completes Enrollment in Study for First Oral Dual Inflammasome Inhibitor for Ophthalmic and Neuroinflammatory Diseases

September 10, 2024

From Inflammasome Therapeutics

Via Business Wire

Inflammasome Therapeutics Announces First Patient Dosed in Geographic Atrophy (GA) Clinical Trial

April 29, 2024

From Inflammasome Therapeutics

Via Business Wire

Inflammasome Therapeutics Announces First Patient Dosed in Phase I Diabetic Macular Edema Study of the Dual Inflammasome Inhibitor K8

January 18, 2024

From Inflammasome Therapeutics

Via Business Wire

Inflammasome Therapeutics to Enter Clinic with Treatment for Dry AMD

November 13, 2023

From Inflammasome Therapeutics

Via Business Wire

New Study Shows Multiple Inflammasomes Combine to Cause Lupus, Macular Degeneration and Other Neuroinflammatory Diseases Such as Alzheimer’s Disease and Multiple Sclerosis

December 06, 2021

From Inflammasome Therapeutics

Via Business Wire

Inflammasome Therapeutics’ CEO to Be Featured Speaker at Upcoming Virtual Summit on Inflammasomes

November 12, 2021

From Inflammasome Therapeutics

Via Business Wire

Inflammasome Therapeutics’ Kamuvudines Continue to Show Promise for Future Treatment – and Potentially a Cure – for Blindness in Seniors

September 30, 2021

From Inflammasome Therapeutics

Via Business Wire

Inflammasome Therapeutics to Develop Dual Sustained-Release HIV Prevention and Birth Control Implant

August 09, 2021

From Inflammasome Therapeutics

Via Business Wire

Inflammasome Therapeutics’ Kamuvudines May Be Answer to Preventing Blindness in Aging Population

April 19, 2021

From Inflammasome Therapeutics

Via Business Wire

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.